Back to Awarded Treatment Trials
Awarded Trial: 01T-080
Grant ID
01T-080
Illness
Schizophrenia
Primary Drug/Intervention
Pergolide
Primary Dosage
0.75mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Sekine
Sample Size
60
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
PANSS, Cognitive Battery, Quality of Life Scale
Results
Patients treated with pergolide showed no significant improvement on PANSS, Quality of Life Scale or cognitive measures when compared to placebo-treated patients.
Publication
N/A
Link
N/A
PI Name
Yoshimoto Sekine
Degree
MD
Center
Department of Psychiatry and Neurology
Institution
Hamamatsu University School of Medicine
Address
1-20-1 Handayama
City or Town
Hamamatsu
State or Province
Shizuoka
Zip or Postal Code
431-3192
Country
Japan
Email Address
ysekine@hama-med.ac.jp